Literature DB >> 22695117

NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.

Yuji Sakuma1, Yukiko Yamazaki, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Shoichi Matsukuma, Shiro Koizume, Yohei Miyagi.   

Abstract

Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cells in suspension undergo apoptosis to a greater extent than adherent cells in a monolayer when EGFR autophosphorylation is inhibited by EGFR tyrosine kinase inhibitors (TKIs). This suggests that cell adhesion to a culture dish may activate an anti-apoptotic signaling pathway other than the EGFR pathway. Since the microenvironment of cells cultured in a monolayer are substantially different to that of cells existing in three-dimension (3D) in vivo, we assessed whether two EGFR-mutant lung adenocarcinoma cell lines, HCC827 and H1975, were more resistant to EGFR TKI-induced apoptosis when cultured in a 3D extracellular matrix (ECM) as compared with in suspension. The ECM-adherent EGFR-mutant cells in 3D were significantly less sensitive to treatment with WZ4002, an EGFR TKI, than the suspended cells. Further, a marked degradation of IκBα, the inhibitor of nuclear factor (NF)-κB, was observed only in the 3D-cultured cells, leading to an increase in the activation of NF-κB. Moreover, the inhibition of NF-κB with pharmacological inhibitors enhanced EGFR TKI-induced apoptosis in 3D-cultured EGFR-mutant cells. These results suggest that inhibition of NF-κB signaling would render ECM-adherent EGFR-mutant lung adenocarcinoma cells in vivo more susceptible to EGFR TKI-induced cell death.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695117     DOI: 10.1016/j.bbrc.2012.06.009

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  DNA copy number profiling in microsatellite-stable and microsatellite-unstable hereditary non-polyposis colorectal cancers by targeted CNV array.

Authors:  Weixiang Chen; Jun Ding; Long Jiang; Zebing Liu; Xiaoyan Zhou; Daren Shi
Journal:  Funct Integr Genomics       Date:  2016-11-28       Impact factor: 3.410

Review 2.  Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Authors:  Kenichi Suda; Paul A Bunn; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-09-15       Impact factor: 15.609

3.  Genome profiling of mismatch repair genes in eight types of tumors.

Authors:  Siqi Wang; Gefei Guan; Cunyi Zou; Qing Guo; Wen Cheng; Shuai Shen; Fang Dong; Anhua Wu; Guang Li; Chen Zhu
Journal:  Cell Cycle       Date:  2021-05-09       Impact factor: 4.534

4.  LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation.

Authors:  Siwen Liu; Haixia Cao; Dan Chen; Shaorong Yu; Huanhuan Sha; Jianzhong Wu; Rong Ma; Zhuo Wang; Changwen Jing; Junying Zhang; Jifeng Feng
Journal:  Oncol Lett       Date:  2018-03-06       Impact factor: 2.967

5.  Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.

Authors:  Nagavendra Kommineni; Ebony Nottingham; Arvind Bagde; Nilkumar Patel; Arun K Rishi; Satyanarayan R S Dev; Mandip Singh
Journal:  Eur J Pharm Biopharm       Date:  2020-11-18       Impact factor: 5.571

6.  Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis.

Authors:  Xiao-Hong Kang; Zhen-Ye Xu; Ya-Bin Gong; Li-Fang Wang; Zhong-Qi Wang; Ling Xu; Fei Cao; Ming-Juan Liao
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-28       Impact factor: 2.629

7.  NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.

Authors:  Xiaoyuan Wang; Hang Yin; Hongxia Zhang; Jing Hu; Hailing Lu; Chunhong Li; Mengru Cao; Shi Yan; Li Cai
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

8.  Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.

Authors:  Wunchana Seubwai; Kulthida Vaeteewoottacharn; Ratthaphol Kraiklang; Kazuo Umezawa; Seiji Okada; Sopit Wongkham
Journal:  Oncol Res       Date:  2016-01-21       Impact factor: 5.574

Review 9.  Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cells       Date:  2021-06-24       Impact factor: 6.600

10.  Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?

Authors:  Kenichi Suda
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.